



ResMed

*Changing lives
with every breath*

Investor Presentation

Q4 2018

Aug 2, 2018

Presentation of Financial Information & Forward-Looking Statements

Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated.

This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com).

In addition to historical information, this presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed’s current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, and tax outlook. Forward-looking statements can generally be identified by terminology such as “may”, “will”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue”, or variations of these terms, or the negative of these terms or other comparable terminology.

ResMed’s expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the “Risk Factors” identified in ResMed’s quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements.

> Overview

Who We Are / What We Do

- World-leading connected health company with more than 5 million cloud-connected devices
 - Enabling care teams in over 65 countries to remotely monitor patients every day
- Innovative designer and manufacturer of award-winning devices and cloud-based software solutions
 - Diagnose, treat, and manage sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions
- Products and solutions designed to improve patient quality of life, reduce impact of chronic disease, and lower healthcare costs
- Cloud-based software health applications and devices designed to provide connected care, improving patient outcomes and efficiencies for healthcare providers
 - Tools that allow fewer people to manage more patients
 - Empower patients to track own health outcomes



➤ Why Invest? – *Driving Long-Term Shareholder Value*



Market Dynamics

- Underpenetrated markets in sleep & COPD
- Healthcare costs continue to increase
- Focus on improving patient outcomes
- Value-based technology solutions



Growth & Innovation

- Global leader in connected health for sleep and respiratory care
- Long-term growth opportunities
- 5,500+ patents and designs
- ~ 7% of revenue invested in R&D



Financial Results

- Historical revenue and profit growth
- Recurring revenue
- Operating excellence program
- Strong track record of disciplined capital deployment

➤ Growth Strategy & Strategic Initiatives

Changing lives with every breath

20 million lives changed in 2020

Improve patient quality of life
 Slow chronic disease progression
 Reduce healthcare system costs

Number of Patient Lives Impacted

Horizon 1 Lead SDB Industry

- Ground breaking end-to-end connected health solutions

Horizon 2 Scale-Up Respiratory Care and Connected COPD

- Connected respiratory care solutions for COPD, obesity-hypoventilation syndrome, and neuromuscular disease, including ALS
- Integrate with connected solutions

Horizon 3 Invest in Portfolio of New Market Options

- Sleep & Consumer Wellness
 - Engagement in Sleep Health
 - Expansion of ResMed brand
- Connected Health Expansion
 - Connected devices, analytics, population health models
 - Out of hospital SaaS Solutions
 - Care coordination
- Adjacent Market Development
 - A-Fib, HFpEF, Asthma

Expansion in High Growth Markets – China, E. Europe, India, Brazil, S.E. Asia

Time to Material Growth Impact

PEOPLE, LEADERSHIP AND CULTURE

GLOBAL LEADERSHIP IN DIGITAL AND CONNECTED HEALTH

OPERATING EXCELLENCE – LEVERAGE MARKET-LEADING SCALE


> Our Business - *Sleep*

⌋ What is Sleep-Disordered Breathing?

- Abnormal respiration during sleep – the cessation of breathing or “sleep suffocation”
- Most prevalent is **obstructive sleep apnea** – collapse of the upper airway despite ongoing effort
- Other types include central sleep apnea -- lack of breathing *and* lack of effort -- and mixed apnea



Normal airway



Partially obstructed airway



Obstructed airway



Arousal

➤ Transforming Treatment & Management of Sleep Apnea

Quiet



AirSense™10



AirSense™10 AutoSet for Her



AirCurve™10

Compact



Comfortable



AirFit™ P10
Nasal Pillows System



AirFit™ N20
Nasal mask



AirFit™ F20
Full face mask



AirTouch™ F20
Full face mask

Connected




AirView™



myAir™



Global Prevalence of Obstructive Sleep Apnea (OSA) Presents Opportunity to Drive Increased Awareness



Benjafield, et al. AJRCCM 2018 (abstract)



➤ Sleep Apnea is More Than 80% Undiagnosed

For every 100 U.S. adults...

4 KNOW THEY HAVE SLEEP APNEA^{1,2}



22 DON'T KNOW THEY HAVE IT^{1,2}

1 Peppard PE et al. *Am J Epidemiol* 2013

2 Young T et al. *Sleep* 1997



Key Demographic, Political, and Healthcare Trends Present Multiple Opportunities for ResMed

Healthcare continues to rise in importance as a major topic on social and political agendas around the world.

MACRO

Increasing Chronic Disease Burden

Aging Population

Healthcare Costs Growing

Physician Shortages

The shift to value-based healthcare and consumerization-of-care is here to stay.

Healthcare System Pain Points

MICRO

Delivering the correct care when needed

Delivering care in lower cost settings

Patient Engagement

Documentation

Data Availability

Communication

Analytics

Integration of **Data & Technology** is KEY to driving increased awareness & treatment

Working with Others to Raise Sleep as a Public Priority



• • •
• **Consumer tech joint venture** with Dr. Oz and Pegasus Capital

• • •
• World's first non-contact sleep tracking mobile app

• • •
• Shows people how they sleep, and how they can improve their sleep



• • •
• **Sleep research joint venture** with Verily¹


• • •
• To study the health and financial impacts of untreated sleep apnea

• • •
• Based on research: Develop software solutions to help identify, diagnose, treat and manage those with OSA

Healthcare Informatics

Leading the Industry with over 2.5 Billion Nights of Medical Sleep and Respiratory Care Data in the Cloud

Global Leader in Cloud-Connected Medical Devices



➤ Global Leadership in Connected Health

AirView™ has over
8 million+ patients

5 million+ patients
monitored at **home** with
connected care

200,000+ diagnostic tests
processed **in the cloud**

Brightree has **64 million+**
patient accounts as part of its
post-acute care network

76 API calls per **second**
from integrators

1 million+ patients have

signed up for **myAir™**

Market-Leading Connected Health Solutions

Pioneering *innovations* and providing *clinical evidence* that support better patient outcomes and improved business efficiencies for customers



AirView™



Labor Costs²



New Patient Setups³



1. Hwang, et al., AJRCCM 2017
2. Munafo, et al. Sleep Breath 2016
3. Data based on monthly patient setups and compliance rates of DME customers from February 2014 – March 2015. Historical results for this provider over the stated time
4. Crocker, et al., Abstract CHEST 2016

myAir™



World's largest study for adherence


> 128,000 patients



➤ Improving Adherence to Therapy

ResAdhere: remote monitoring + mask resupply drive improved adherence

In a study of ~100k patients with AirView cloud-connected devices...



...the likelihood of therapy termination decreased by >50% after one-year and there was a significant increase in daily PAP usage

Benjafeld, et al. AJRCCM 2018 (abstract)

Note: De-identified data from Brightree and AirView were sent to a third-party independent statistician who provided the anonymized analyses and findings.




Big Data Analysis Drives Insights for Treatment of Central Sleep Apnea

Patients with treatment-emergent central sleep apnea (CSA) are two times more likely to terminate therapy

- Opportunity to rethink conventional therapeutic options
- Minimize risk of therapy termination through early diagnosis
- Regularly monitor patients to support adherence to treatment



Analysis of ~200k CSA patients



- Switching from therapy CPAP to ASV improved relative adherence by 22%
- Patients who switched from CPAP to ASV had fewer apneas and hyponeas during sleep



➤ Our Business - *Respiratory Care*

⊙ What is Chronic Obstructive Pulmonary Disease (COPD)?

COPD is a serious lung disease that over time, makes it hard to breathe

The leading cause of COPD is smoking


Other causes include:

- second hand smoke
- pollution
- occupational exposure to noxious gases
- a history of childhood infections (could be a catalyst)
- genetic inheritance, leading to its onset



➤ COPD is a Large and Growing Market

- COPD is the third leading cause of death worldwide¹
- More than 380 million people worldwide are estimated to have COPD²
 - Largely undiagnosed COPD sufferers in high-growth markets such as China, India, Brazil and E. Europe may be well over 100 million³
- Cost to healthcare systems from COPD is enormous:
 - Europe: ~€48 billion per year⁴
 - US: ~\$50 billion per year⁵
- More than 3 million people worldwide die each year due to COPD⁶



¹World Health Organization. The top 10 causes of death: Fact sheet: No310 (2014, May) accessed 20Jul16

²Ferkol T et al. Annals ATS 2014

³Company estimates based on World Health Organization estimates and Zhong et al. "Prevalence of Chronic Obstructive Pulmonary Disease in China" *Respiratory and Critical Care*

⁴European Respiratory Society, *European Lung White Book* <http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/> accessed 20Jul16


⁵Guarascio et al. Dove Med Press, 2013 Jun 17

⁶World Health Organization. Chronic obstructive pulmonary disease (COPD): Fact sheet No315. 2015 accessed 20Jul16

➤ Opportunity to Shift Care from Hospital to Home

- Healthcare costs are on the rise
- Combining non-invasive ventilation (NIV) with home oxygen therapy (HOT)
 - Reduces hospitalization and mortality by 51%
 - Increases time to hospital readmission or death by ~90 days

JAMA[®]
The Journal of the American Medical Association



- Combination of HOT with NIV reduced hospital readmissions by 58.3%
- Combination of therapies provided improved patient quality of life and saved >\$50k per quality of life adjusted year

1 P. Murphy et al., *Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation. A Randomized Clinical Trial*, JAMA. Published online May 21, 2017. doi:10.1001/jama.2017.4451.

➤ Full Spectrum of Solutions for Respiratory Care

High-Flow Therapy



AcuCare™ high flow

Portable Oxygen Concentrator



Mobi™

Bilevel Ventilation



AirCurve 10

Non-invasive Ventilation (NIV)



Lumis™



Stellar™

Life Support Ventilation



Astral™




Astral™ with RCM

➔
Patient Acuity

➤ Our Business - *Software as a Service (SaaS)*

Global Leader in End-to-End Solutions...

...for Sleep and Respiratory Care



History of Successful SaaS Acquisitions and Integrations

Company	Location	Date	Key Product	Status
	Halifax, NS Canada	AUG 2012	U-Sleep	Fully integrated as AirView Action Groups. Halifax has become key PD development center and provider of Saas Services
	Knoxville, TN	FEB 2015	GoJaysec	Rebranded as GoScripts referral document management service. Now interoperable with Brightree
	Denver, CO	JUL 2015	CareTouch 360	Rebranded as ResMed Resupply, reaching over 100k patients across 80 customers
	Lawrenceville, GA	FEB 2016	Brightree Core	Continues to operate as a wholly owned subsidiary with strong growth across its various modules
	Girard, PA	JUN 2017	MyForms	Integrated into Brightree, enhancing custom forms builder and workflow solutions for HME providers
	Joliet, IL	JUL 2017	Brightree ConnectPRO	Now part of Brightree Services, providing live call center services to Brightree customers
	Springfield, MO	JUL 2018	firstHOMECARE Software (EHR)	Will operate as a wholly owned subsidiary providing software solutions and services for home health and hospice customers

Software as a Service (SaaS): Brightree

Leading
Provider

Brightree is the **leading provider** of cloud-based software to improve clinical and business performance in the post-acute care industry

2,500
Orgs

Serves more than **2,500 organizations** in the HME, home health, hospice, orthotic and prosthetic, HME pharmacy, home infusion and rehabilitation home care segments.

Top
100

Ranked one of the **top 100 healthcare IT companies** in the U.S. on the prestigious Healthcare Informatics 100 (HCI 100) list

AirSolutions

AirView™
DIAGNOSTICS

AirView™

U-Sleep

GoScripts™

ReSupply

myAir™

ResMed
Data Exchange

Brightree Modules

for core HME customers as well as new Home Health and Hospice channels

Core HME Platform

- Billing & Inventory Management
- Reporting & Analytics

Home Health & Hospice

- Native iPad® point-of-care app
- Cloud-based back-office EMR

Physicians Referrals

- Referral Processing & Documentation
- Eligibility Verification

Document Management

- Capture, manage, share & secure
- Automated rules & workflows

Revenue Cycle Mgmt

- Outsourced Billing & Consulting
- Intake Management

Inventory Management

- Purchasing & Intake
- Delivery & Fulfillment

Patient Resupply

- Multichannel Patient Contact Campaigns
- Automated Patient Interaction

Patient Collections

- Automated Patient Pay Technology
- Best Practices Consulting

> Expanding ResMed's SaaS Offerings



Acquired: July 9, 2018

- EHR software, billing and coding services, analytics for **home health and hospice agencies**
- Segments are large and growing, along with the prevalence of chronic disease and seniors shifting to homecare and other lower-cost care settings
- Customer network and SaaS offerings complement existing offerings from Brightree

➤ Financial Results


> Key Financial Results

	Q4 2018	FY 2018
Revenue	\$623.6M +12% (+10% CC)	\$2,340.2M +13% (+10% CC)
Gross margin	58.1%	58.2%
Non-GAAP operating profit*	\$166.0M +19%	\$606.6M +19%
Non-GAAP net income*	\$136.3M +24%	\$507.8M +27%
Non-GAAP EPS*	\$0.95 +23%	\$3.53 +25%
Cash flow from operations	\$129.4M	\$505.0M
Free cash flow	\$111.8M	\$442.4M

* ResMed adjusts for the impact of the amortization of acquired intangibles, impact of U.S. tax reform, and restructuring expenses, from their evaluation of ongoing operations and believes investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

➤ Diversified Revenue – by Geography & by Business


Europe,
Asia and
Other
38%



US, Canada
and Latin
America
62%

OOH SaaS
6%

Masks and
Accessories
37%




Devices
56%


Note: Represents Q4 2018 revenue breakdown

Track Record of Disciplined Financial Growth


Revenue (\$B)



Adjusted EPS



Quarterly dividend




Fiscal Years ended June 30




Focus on Operating Excellence is Driving Improved Operating Leverage

Operating Profit **24.6%** **25.9%**



Capital Deployment



Investment for Growth

- New Products
- Geographic expansion
- Acquisitions



Free Cash Flow returned to Shareholders

- Last twelve months combined dividend and stock repurchase = 57% of free cash flow



Increasing Dividend

- FY 2018 dividend payout ratio of 39% of Adj. net income
- Dividend per share increased by 6% over prior year

Combined dividend and buy-back over rolling 5 years
= **71% of free cash flow**

⊙ Changing Lives with Every Breath

*In the last 12 months, we changed
more than **14 million lives.***

*Our aspiration is to change
20 million lives by 2020*

➤ Why Invest? – *Driving Long-Term Shareholder Value*



Market Dynamics

- Underpenetrated markets in sleep & COPD
- Healthcare costs continue to increase
- Focus on improving patient outcomes
- Value-based technology solutions



Growth & Innovation

- Global leader in connected health for sleep and respiratory care
- Long-term growth opportunities
- 5,500 + patents and designs
- ~ 7% of revenue invested in R&D



Financial Results

- Historical revenue and profit growth
- Recurring revenue
- Operating excellence program
- Strong track record of capital deployment



Contact Investor Relations

Phone: (858) 836-5971

Email: investorrelations@resmed.com

Website: www.investors.resmed.com